1-3 of 3
Danjie Zhang
Close
Sort by
Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Eugen Tausch, Volkmar Boehme, Matthias Ritgen, Ruediger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Stephan Stilgenbauer, Danjie Zhang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4297.
https://doi.org/10.1182/blood-2019-130912
Published: 2019
Journal Articles

Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway

Jeffrey P. Sharman, Andrei R. Shustov, Mitchell R. Smith, Christopher T. Hagenstad, Kathryn S. Kolibaba, Esteban Abella-Dominicis, Danjie Zhang, Siddhartha Mitra, Christopher A. Yasenchak, Farrukh T. Awan
Journal: Blood
Blood (2016) 128 (22): 3225.
https://doi.org/10.1182/blood.V128.22.3225.3225
Published: 2016
Journal Articles

Results of a Phase 2 Trial Evaluating Efficacy and Safety of Entospletinib (GS-9973) in Patients with Mantle Cell Lymphoma

Jeffrey P. Sharman, Kathryn S. Kolibaba, Andrei R. Shustov, Thomas A. Giever, Leonard M. Klein, Derek Nay, Thomas A. Rado, Alfred Saleh, Danjie Zhang, Wen Shi, Andres Forero, Sarit Assouline
Journal: Blood
Blood (2016) 128 (22): 2963.
https://doi.org/10.1182/blood.V128.22.2963.2963
Published: 2016